Although variable, the prognosis of ocular BD is poor in the majority of patients. Nevertheless, increased awareness of the disease, a more aggressive treatment approach and the availability of ...
24/7 Wall St. on MSN12h
AbbVie Just Paid Investors: Here's How Much They ReceivedAbbVie just rewarded its shareholders again with a dividend. This stock has boosted its payout annually for more than 50 ...
Gladstone Institutional Advisory LLC trimmed its holdings in Amgen Inc. (NASDAQ:AMGN – Free Report) by 18.9% in the fourth ...
Amgen (NASDAQ:AMGN – Get Free Report) had its target price increased by Piper Sandler from $310.00 to $329.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage currently ...
Treatment with infliximab vs interferon-α2a led to similar improvements in disease activity, ocular symptoms, ulcers, and pain among patients with Behçet syndrome. Infliximab and interferon-alpha (α) ...
Treatment with infliximab vs interferon-α2a led to similar improvements in disease activity, ocular symptoms, ulcers, and pain among patients with Behçet syndrome. Infliximab and interferon ...
More recently Robinson 4 suggested that these groups of eruptions of undetermined etiology be classified as the "ocular-mucous membrane ... Stevens-Johnson disease, ectodermose erosive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback